Aran, A., Hacohen, M., Caspi, L., & Lavi, I. (2019). Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284–1288.
Aran, A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., Bentur, Y., & Castellanos, F. X. (2019). Lower circulating endocannabinoid levels in children with autism spectrum disorder. Molecular Autism, 10(1), 2.
Aran, A., et al. (2021). Cannabinoid treatment for autism: A proof-of-concept randomized trial. Molecular Autism, 12(1), 6.
Avalos, L. A., Hendrick, C. E., Li, D.-K., Quesenberry, C. P., Gorman, J. R., & Croen, L. A. (2024). Maternal prenatal cannabis use and child autism spectrum disorder. JAMA Network Open, 7(10), e2440301–e2440301.
Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life experience of medical cannabis treatment in autism: Analysis of safety and efficacy. Scientific Reports, 9(1), 200.
El-Sukkari, D., et al. (2023). Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in children with autism spectrum disorder: An open-label study. MedRxiv. https://doi.org/10.1101/2023.12
Erridge, S., et al. (2022). Clinical outcome analysis of patients with autism spectrum disorder: Analysis from the UK Medical Cannabis Registry. Therapeutic Advances in Psychopharmacology, 12, 20451253221116240.
Fleury-Teixeira, P., Caixeta, F. V., Ramires da Silva, L. C., Brasil-Neto, J. P., Malcher-Lopes, R., & Ribeiro, A. M. (2019). Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10, 1145.
Fletcher, S., Arnold, C., Houghton, R., & Little, S. (2022). Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review. Child: Care, Health and Development, 48(1), 33–44.
Hacohen, M., Aran, A., Eylon, M., & Meiri, G. (2022). Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open-label study. Translational Psychiatry, 12(1), 375.
Hurley, E. N., Cutshall, N. S., Eaton, E. A., Reisinger, D. L., Sutcliffe, J. S., & Anderson, A. E. (2022). Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia, 63(7), 1736–1747.
Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9(1), 18.
Kurz, R., & Blaas, K. (2010). Use of dronabinol (delta-9-THC) in autism: A prospective single-case study with an early infantile autistic child. Cannabinoids, 5(4), 4–6.
Mazza, J. A. de S., Knap, L. M., de Souza, M. P., Silva, A. L. B., & Crippa, J. A. (2024). Clinical and family implications of cannabidiol (CBD)-dominant full-spectrum phytocannabinoid extract in children and adolescents with moderate to severe non-syndromic autism spectrum disorder (ASD): An observational study on neurobehavioral management. Pharmaceuticals, 17(6), 686.
Pretzsch, C. M., et al. (2019). Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without autism spectrum disorder (ASD): A single dose trial during magnetic resonance spectroscopy. Translational Psychiatry, 9(1), 313.
Sacco, R., Riccitelli, G. C., Disanto, G., Bogousslavsky, J., Cavelti, A., Czell, D., ... & Zecca, C. (2024). Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study. Journal of Clinical Medicine, 13(10), 2907.
Siani-Rose, M., Cox, S., Goldstein, B., Abrams, D., Taylor, M., & Kurek, I. (2023). Cannabis-responsive biomarkers: A pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with autism spectrum disorder. Cannabis and Cannabinoid Research, 8(1), 126–137.
Silva Junior, E. A. da, et al. (2024). Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind, and placebo-controlled clinical trial. Trends in Psychiatry and Psychotherapy, 46, e20210396.
Siniscalco, D., Sapone, A., Giordano, C., Cirillo, A., de Novellis, V., de Magistris, L., Rossi, F., & Maione, S. (2013). Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. Journal of Autism and Developmental Disorders, 43(11), 2686–2695.
Snell, A., & Tesch, T. (2021). Cannabigerol Effects on Body and Liver Weights in Methionine-& Choline-Deficient Diet Induced NASH Mice Model.
Stolar, O., et al. (2022). Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Frontiers in Pharmacology, 13, 977484.
Zamberletti, E., Rubino, T., & Parolaro, D. (2021). Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. Pharmacology & Therapeutics, 226, 107878.
Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Cenini, G., Parolaro, D., & Rubino, T. (2019). Cannabidivarin treatment ameliorates autism-like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in rats. Frontiers in Cellular Neuroscience, 13, 367.
